Navigation Links
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Date:2/19/2008

ls' R&D and clinical activities and operations; the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to Memory Pharmaceuticals. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), ... on cardiac and vascular surgery, announced today that it ... of Vice President, Research and Development; and David P. ... Market Development Surgical Adhesives and Starch Medical Relations.  Dr. ...
... LOUIS, Jan. 4, 2012 Express Scripts now provides ... HealthBridge Pharma & Biotech services. CuraScript, a wholly owned ... suite of services, will be among a limited number ... EYLEA (aflibercept) Injection was approved by the ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5Express Scripts HealthBridge Pharma & Biotech to Provide Specialty Pharmacy and Specialty Distribution Services for EYLEA™ (aflibercept) Injection 2
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... confirmed today that its Krames Patient Education content is ICD-10 ready and available ... ready for the new ICD-10 code sets, which are more targeted and return ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, the ... professional Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko competes ... training and recovery. , With a focus on technology and comfort, Zensah® has ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of Philosophy ... doctoral program at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s ... prepare advanced practice nurses for the highest level of clinical nursing practice. , ...
(Date:8/27/2015)... CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development ... to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Market ... market research promotion on the Internet. MarketPublishers.com is now authorised to distribute ... the partnership agreement, Natalie Aster, Assistant Manager at Partners Department, noted: "Black ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... among those who drink 100% juice, but not all experts ... Children who drink 100 percent fruit juices apparently don,t tend ... than kids who don,t drink the beverages, a new study ... children," said lead researcher Theresa A. Nicklas, a professor of ...
... June 3 The nonpartisan Employee,Benefit Research Institute ... estimates of the amount of money individuals and ... in retirement. The new estimates,attempt to provide more ... with the financial consequences of longevity and investment ...
... 67% Say Less Likely to Re-Elect Member of ... WASHINGTON, June 3 As Congress prepares to,reconvene ... the,American Health Care Association (AHCA) released the results ... that seventy percent of,likely U.S. voters oppose an ...
... Market competition is,mounting to win the time, attention ... research shows that the most sought-after,clinical investigation sites ... they receive at their labs and clinics. Consequently,leading ... the art,and science of investigator recruitment., The ...
... of Women Business Owners Members Voice Their,Opinions on National ... state of the,economy, the cost and availability of health ... are the top issues impacting the,women,s business community at ... the National Association of Women Business Owners(R),(NAWBO(R)) among its ...
... area , , TUESDAY, June 3 (HealthDay News) -- When ... system to target malignancies, it was hoped that the therapy ... without affecting healthy tissue. , While the original theory is ... effects. , The findings, published in the June 10 issue ...
Cached Medicine News:Health News:Fruit Juice May Be Healthy for Kids: Study 2Health News:Fruit Juice May Be Healthy for Kids: Study 3Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 2Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 3Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 4Health News:New Research From EBRI: Estimates Show More Precise Retiree Health Savings Needs 5Health News:70% of U.S. Voters Oppose Administration's Cuts to Medicare-Financed Nursing Home Care 2Health News:Best Practice Toolkit Supports Recruitment of Top Clinical Investigators 2Health News:Economy, Health Care, and Gas Prices Top Issues for Women Business Owners 2Health News:Dangerous Side Effect Found in Cancer Immunotherapy Research 2
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... The Blue Line UNO Splint fits small, medium, ... cushioned two-part design includes both dorsal and volar ... extension. Recommended for those experiencing symptoms of Carpal ... for busy clinics - stock one splint to ...
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
Medicine Products: